Jubilant Organosys has invested Rs 70 crore to set up a drug discovery center at Bangalore. The new 'Jubilant Discovery Center' is the largest of its kind and would provide innovative solutions to global pharmaceuticals and the sciences companies.
The facility located at Yeshwantapur off the Peenya-Bangalore Road, spans an area over 125,000 sq. ft. The center has hired 500 scientists specializing in multiple disciplines including biology, chemistry, structural biology, pharmacology, molecular modeling, crystallography and information technology to collaborate with the their global counterparts in US, Europe and Japan.
This integrated facility at Bangalore houses capabilities in molecular modeling, protein crystallography, medicinal chemistry and invitro-invivo biology capabilities.
"The establishment of the Jubilant Discovery Center is a commitment to innovation led growth. Over the last few years, we have emerged as an integrated pharma company. Today our drug discovery and research operations is a growing business and we expect our investments in multiple therapeutic areas", stated Shyam S Bhartia, chairman and managing director, Jubilant Organosys.
"The Bangalore center is the fourth discovery center for the company. We have three subsidiary companies in India: Jubilant Biosys for discovery informatics and drug discovery services, Jubilant Chemsys for functional chemistry and Clinsys India for clinical research and bioavailability/bio equivalence studies," said Hari S Bhartia, co-chairman and managing director, Jubilant Organosys.
In 2001, the company as part of its efforts to integrate its discovery research activities has founded Jubilant Biosys in a pioneering endeavor to offer informatics solutions to the global pharma sector and create a platform to establish the country's first drug discovery facility.
The Jubilant Discovery Center focuses on collaborative development of novel molecules of interest that have potential therapeutic use to treat diseases in the areas of cancer, metabolic disorders like diabetes, obesity, cardio vascular diseases, tuberculosis, and HIV. Further the center engages itself in academic collaboration to develop enabling technology as well as biology.
Jubilant is among the leading custom research and manufacturing services (CRAMS) and drug discovery and development services provider in the country. The company has international subsidiaries in US, Belgium and China. Its operations in US for generics manufacture is a USFDA approved facility. Clinsys Inc. in Belgium is a full service clinical research organization providing clinical data management and biostatistics.
Jubilant Organosys manufactures API like Carbamazepine, Oxcarbazepine and Citalopram, pyridine and its derivatives, solid polyvinyl acetate, vinyl pyridine latex and organic intermediates like ethyl acetate and acetic anhydride.
The Delhi based company clocked sales of US $337 million in FY2006.